AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06594380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic bite group (control group)
Description: Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
Study NCT06587581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants from the intervention group will receive the usual care over the 6-month intervention period
Study NCT06587581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
Study NCT05393791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-specific adaptive therapy
Description: Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped >50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines >50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
Study NCT05393791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Use of abiraterone or enzalutamide
Study NCT05393791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Use of abiraterone or enzalutamide
Study NCT05393791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Use of abiraterone or enzalutamide
Study NCT05393791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Use of abiraterone or enzalutamide
Study NCT06615206 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG204
Description: The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
Study NCT06672406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuterii
Description: Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding > 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics
Study NCT06600464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound.
Study NCT06600464 — intervention group
Intervention type: OTHER
Intervention: Assessment of Muscle Strength in Both Hands
Description: Muscle strength in both hands was evaluated using grip strength measured with a dynamometer (Jamar Hydraulic Hand Dynamometer, Nottinghamshire, UK)
Study NCT06600464 — intervention group
Intervention type: OTHER
Intervention: Assessment of Pain Threshold
Description: Pressure pain threshold (PPT) for painful and non-painful finger joints was assessed using a hand-held algometer
Study NCT06407921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: On vibration plate pate child will do kneeling, and one leg standing, standing horizontally or vertically. Along routine physical therapy such as stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, elbow and wrist flexors, pronators, and ulnar deviators, each stretch will be given for 30 seconds with 3 repetitions.Strength training to hip flexor, knee extensor, and ankle dorsiflexors for 15 minutes 3 times a week for 8 weeks. Session will be of 30 minutes
Study NCT06407921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOSU ball
Description: Exercises such as (1) standing on a BOSU ball while throwing and catching a ball (2) 1-legged standing (affected leg) on the BOSU ball while throwing and catching a ball with therapist support; and (3) small jumps on the BOSU ball. Three sets of 6 repetitions for each exercise will be perform every 2 weeks up to a maximum of 10 repetitions if the participants were still able to perform the training easily. Total dose of balance training in 1 session will be 15 minutes
Study NCT06700135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensorimotor stimulation program sessions
Description: The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
Study NCT06700135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensorimotor stimulation program sessions
Description: The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
Study NCT06700824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTR4132
Description: OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
Study NCT06700824 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study NCT05856422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory rate measure based on PPG
Description: Testing was conducted under normal office environment conditions. Each subject was connected to the reference EtCO2 monitor (GE Datex-Ohmeda) and the Device Under Test, the Gabi SmartCare Gabi Band. A waveform collected from an EtCO2 measurement was used to determine performance of respiratory rate metrics. Each subject was given a nasal cannula that allowed for measurement of the EtCO2 respiratory rate.~The reference respiratory rate was measured simultaneously with the Device Under Test. Data was marked for stable quiet periods that were useable for analysis.
Study NCT06702072 — intervention group
Intervention type: DEVICE
Intervention: Endobronchial valve treatment
Description: Endobronchial valve treatment
Study NCT06705738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SUPOL
Description: Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
Study NCT06705738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SUPOL
Description: Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
Study NCT06705738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Pattern: MeDi
Description: Adherance to Mediterranean dietary pattern to be followed for 12 months.
Study NCT06705738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Pattern: MeDi
Description: Adherance to Mediterranean dietary pattern to be followed for 12 months.
Study NCT06705361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent Radial Artery Band (Screw-Type)
Description: The researcher will randomly assign patients undergoing radial arterial line removal after open heart surgery into four groups: ice-bag pressure, transparent radial band compression device (screw type), transparent radial band compression device (air type), and control group. The researcher will assign specific card colors to each group: white for the control group, yellow for the ice-bag pressure group, pink for the Transparent Radial Band Compression Device - Screw Type group, and green for the Transparent Radial Band Compression Device - Air Type group. The researcher will place all these cards in a container, allowing the participant to select their preferred color, and then apply the intervention separately to each group.
Study NCT06706427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGGT001
Description: Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
Study NCT06706401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesanoid
Description: Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
Study NCT06706401 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
Study NCT06706401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
Study NCT06706401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tailored radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy over 6 weeks (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
Study NCT06706401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks).
Study NCT06706401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks).
Study NCT06706401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2.
Study NCT06706401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2.
Study NCT06705803 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate Ablation
Description: Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
Study NCT06705478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER
Description: Tablets self-administered orally
Study NCT06705478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Tablets self-administered orally
Study NCT06704880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: children in the CIMT group will RECIEVE lower limb CIMT for the non-hemiplegic limb using whole leg orthosis. Children in cross-education group will receive strengthening training for the non-hemiplegic lower limb
Study NCT06706414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: Subcutaneous injection with 60 mg Denosumab once
Study NCT06705751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Autonomic response in AAOCA
Description: Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited.~Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch.~The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions.
Study NCT06705179 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral task performance
Description: Measures of performance on behavioral tasks
Study NCT06705114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: complete denture
Description: Each patient received a newly constructed conventional complete denture with optimal denture extension and lingualized balanced occlusal concept
Study NCT06705114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant overdenture
Description: Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.After 3-4 months, the dental implants were exposed and ball abutments were screwed into the implants. The housing of the ball attachments were incorporated into the fitting surface of the mandibular denture using a direct pick-up technique (Fig. 1B). The mandibular overdenture was then inserted into the patient's mouth and occlusal adjustment was done using articulating paper to remove any occlusal interferences. Follow-up visits were scheduled.
Study NCT06705283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga and home exercise
Description: The intervention period for the study was determined as 6 weeks. It has been decided that yoga practice will be done 3 times a week for 45 minutes.~Poses to be practiced in the yoga group:~1. Tadasana (mountain pose)~2. Utkatasana (chair pose)~3. Trikonasana (triangle pose)~4. Malasana (squat pose):~5. Viparita Karani Variation (legs up the wall pose)~6. Salamba Set Bandhasana (supported bridge pose)~7. Supta Baddha Konasana (reclining bound angle pose)~8. Savasana (dead pose)
Study NCT06705283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body vibration training and home exercise
Description: A total of 40-45 minutes of training was planned for WBVT, including warm-up (10 minutes), active phase (25-30 minutes) and cooling phase (5 minutes).
Study NCT06705283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home exercise group
Description: Pelvic floor muscle training will be done in the home exercise group. This training will be done in the form of slow and fast contractions of the pelvic floor muscles in supine, chin up, sitting, squat and standing positions.
Study NCT05241873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-451
Description: BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
Study NCT05241873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
Study NCT05241873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
Study NCT06464458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: management on hydroxyurea by therapeutic pharmacological monitoring
Description: HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance.
Study NCT05622734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOCALE LBD+
Description: Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
Study NCT06173830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: 34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
Study NCT06173830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: 34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
Study NCT06088888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
Study NCT04697667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise program
Study NCT04697667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise program
Study NCT04697667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Intra-articular PRP injections to knee joint
Study NCT04697667 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Intra-articular PRP injections to knee joint
Study NCT05410522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS Program
Description: Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
Study NCT06290115 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set 1
Description: Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
Study NCT06290115 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set 2
Description: Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
Study NCT06290115 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set 3
Description: Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.